A proposed comprehensive pathophysiology of thrombotic thrombocytopenic purpura with implicit novel tests and therapies.
The first detailed comprehensive hypothesis for the pathophysiology of TTP is proposed which accounts for all of the features of TTP at several levels of reference: clinical, physiologic, biochemical, hematologic, and tissue pathology. From the proposed pathophysiology, by deduction, a number of novel diagnostic tests and several rational, promising therapeutic modalities.
D001803:Blood Transfusion; D004727:Endothelium / Q000503:physiopathology; D005078:Exchange Transfusion, Whole Blood; D005353:Fibronectins; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D046911:Macromolecular Substances; D012157:Mononuclear Phagocyte System / Q000503:physiopathology; D010949:Plasma / Q000637:transplantation; D010960:Plasminogen Activators; D010974:Platelet Aggregation / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D011509:Proteoglycans; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D013256:Steroids / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use; D001620:beta-Thromboglobulin
D005353:Fibronectins; D046911:Macromolecular Substances; D011453:Prostaglandins; D011509:Proteoglycans; D013256:Steroids; D001620:beta-Thromboglobulin; D014810:Vitamin E; D006493:Heparin; D011451:Prostaglandin-Endoperoxide Synthases; D010960:Plasminogen Activators